绥美凯推荐剂量

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline (hereinafter referred to as GSK), the first complete antiviral treatment regimen drug with dolutegravir (also known as DTG in English) as the core, was officially launched in China. This is also the first complete single-pill compound treatment regimen in the field of HIV treatment in China.

Suimeikai is a compound medicine. Each tablet contains dolutegravir sodium 50mg, abacavir sulfate 600mg, and lamivudine 300mg. It is suitable for treating HIV adults and patients over 12 years old. Among them, the dolutegravir component can block the strand transfer of DNA integration through binding to the integrase active site, which is one of the key steps for HIV replication, thereby inhibiting HIV integrase in the body. For adults and adolescents, the dosage of Suimei is one tablet, once a day. When the weight is less than 40kg, this drug generally cannot be used. This drug is a fixed-dose preparation and the dosage cannot be reduced. This dosage of Suimeikai cannot be used on patients who need to adjust the dosage.

Suimeikai is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK launched the integrase DTG (Trivic) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Trimic uses DTG, an integrase inhibitor, as the core drug, combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making great progress in the core drug in HAART treatment. In addition, it can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.